February 1, 2018 / 12:14 PM / 9 months ago

BRIEF-Syndax Announces Immuno-Oncology Clinical Trial Collaboration With Astrazeneca

Feb 1 (Reuters) - Syndax Pharmaceuticals Inc:

* SYNDAX ANNOUNCES IMMUNO-ONCOLOGY CLINICAL TRIAL COLLABORATION WITH ASTRAZENECA

* SYNDAX PHARMACEUTICALS INC - CO & ASTRAZENECA TO COLLABORATE ON NON-EXCLUSIVE BASIS TO EVALUATE COMBINATION OF TWO DRUGS IN MULTIPLE SOLID TUMOR TYPES

* SYNDAX PHARMACEUTICALS INC - SYNDAX EXPECTS TO INITIATE A PHASE IB STUDY IN FIRST HALF OF 2018

* SYNDAX PHARMACEUTICALS INC - FINANCIAL AND OTHER TERMS OF AGREEMENT WERE NOT DISCLOSED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below